FMI - Foundation Medicine, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
136.70
+0.30 (+0.22%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close136.40
Open136.45
Bid136.45 x 800
Ask137.85 x 900
Day's range136.40 - 136.70
52-week range31.70 - 137.20
Volume1,044,756
Avg. volume488,254
Market cap5.063B
Beta1.63
PE ratio (TTM)N/A
EPS (TTM)-4.21
Earnings date30 Jul 2018 - 3 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est92.50
Trade prices are not sourced from all markets
  • Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
    Zacks19 hours ago

    Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI

    Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.

  • Motley Fool19 hours ago

    Big Biotech Stock Pops and Drops This Week

    Foundation Medicine, Sarepta Therapeutics, and PTC Therapeutics reported market-moving news that every biotech investor ought to know about.

  • The Wall Street Journal21 hours ago

    [$$] Gormley's Take: Precision-Medicine Drive Gathers Momentum

    Last month, the American Cancer Society expanded opportunities for colorectal cancer-testing companies when it called for people with average risk profiles to begin screening at age 45 instead of 50. Inc., which went public in 2005, said clinical trials showed its Oncotype DX test could definitively identify which early-stage breast cancer patients would and wouldn’t benefit from chemotherapy—news that propelled its stock price to all-time highs. Inc., which Third Rock Ventures formed in 2009 and took public in 2013.

  • Company News For Jun 20, 2018
    Zacks3 days ago

    Company News For Jun 20, 2018

    Companies in the news are: T,FMI,COTV,SRPT

  • Roche to Buy Rest of Foundation Medicine for $2.4 billion
    Zacks3 days ago

    Roche to Buy Rest of Foundation Medicine for $2.4 billion

    Roche inks a deal with Foundation Medicine to acquire the remaining shares of Foundation Medicine, not already owned by it for a total consideration of $2.4 billion.

  • The Wall Street Journal3 days ago

    [$$] Roche to Pay $2.4 Billion for Full Control of Foundation Medicine

    Roche Holding AG on Tuesday said it would pay $2.4 billion to buy the shares it doesn’t already own in Foundation Medicine Inc., furthering its bet on personalized cancer care. The Swiss drug giant, which already owns roughly 57% of Foundation, will pay $137 a share for the U.S.-based company, valuing it at $5.3 billion. Cambridge, Mass.-based Foundation makes molecular-diagnostic tests that identify alterations in a patient’s cancer.

  • Why CVS Health, Foundation Medicine, and Solid Biosciences Jumped Today
    Motley Fool3 days ago

    Why CVS Health, Foundation Medicine, and Solid Biosciences Jumped Today

    Find out why healthcare made a big leap in today's market action.

  • How A Merger Will Help These Two Firms Tailor Cancer Treatments
    Investor's Business Daily3 days ago

    How A Merger Will Help These Two Firms Tailor Cancer Treatments

    Foundation Medicine rocketed to a record high Tuesday after Swiss drugmaker Roche agreed to buy it in a pharmaceutical merger for $2.4 billion.

  • Roche Does Pharma M&A Without the Pharma
    Bloomberg4 days ago

    Roche Does Pharma M&A Without the Pharma

    The Swiss giant agreed Tuesday to pay $2.4 billion to buy out the remaining shareholders in Foundation Medicine Inc., a cancer-focused gene sequencing company in which it holds a more than 50 percent stake. It follows Roche's $1.9 billion purchase earlier this year of Flatiron Health Inc., which collects and analyzes real-world data on how cancer patients are treated. These were Roche’s two biggest deals since 2014. The Foundation deal comes at a hefty premium, and may be a disappointment to investors who would have preferred a more typical acquisition focused on an actual, existing drug.

  • Why Foundation Medicine Stock Is Skyrocketing 28.3% Higher Today
    Motley Fool4 days ago

    Why Foundation Medicine Stock Is Skyrocketing 28.3% Higher Today

    The company's being acquired by long-time partner Roche Holdings.

  • Netflix expands, Amazon teams up with Marriott, Wells Fargo merging wealth management groups
    Yahoo Finance4 days ago

    Netflix expands, Amazon teams up with Marriott, Wells Fargo merging wealth management groups

    Netflix, Amazon, Wells Fargo, Roche and Apple are the companies to watch.

  • Stocks fall deep into the red as trade war escalates
    Yahoo Finance4 days ago

    Stocks fall deep into the red as trade war escalates

    Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:25 a.m. ET.

  • The Wall Street Journal4 days ago

    [$$] European Corporate Roundup for Tuesday

    A $2.4 billion Roche acquisition and another Debenhams profit warning are the European corporate highlights Tuesday.

  • Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
    Reuters4 days ago

    Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

    ZURICH/LONDON (Reuters) - Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI), raising its bet on the U.S. genomic profiling group's ability to personalise cancer care. The deal, backed by the boards of both companies, is worth $137 per share - a premium of 29 percent to FMI's closing price on Monday - valuing the Cambridge, Massachusetts-based company at $5.3 billion. It is the latest in a series of bolt-on acquisitions by Roche as the world's largest marker of cancer drugs seeks to tap into promising technology developed by biotech companies to drive future growth as its older drugs face competition.

  • The Wall Street Journal4 days ago

    [$$] Roche to Buy Rest of Foundation Medicine

    The Swiss drug giant, which already owns roughly 57% of Foundation, will pay $137 a share for the U.S.-based company, valuing it at $5.3 billion. Cambridge, Mass.-based Foundation makes molecular-diagnostic tests that identify alterations in a patient’s cancer. The deal to take full control of Foundation comes after Roche first bought a stake in the company in 2015.

  • Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
    Reuters4 days ago

    Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

    ZURICH/LONDON (Reuters) - Swiss drugmaker Roche (ROG.S) is paying $2.4 billion to buy the rest of Foundation Medicine (FMI) (FMI.O), raising its bet on the U.S. genomic profiling group's ability to personalize cancer care. The deal, backed by the boards of both companies, is worth $137 per share - a premium of 29 percent to FMI's closing price on Monday - valuing the Cambridge, Massachusetts-based company at $5.3 billion. It is the latest in a series of bolt-on acquisitions by Roche as the world's largest marker of cancer drugs seeks to tap into promising technology developed by biotech companies to drive future growth as its older drugs face competition.

  • GlobeNewswire4 days ago

    Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology

    OTCQX: RHHBY) and Foundation Medicine, Inc. (FMI) today announced they have entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI`s common stock not already owned by Roche and its affiliates at a price of US$ 137.00 per share in cash. This corresponds to a total transaction value of US$ 2.4 billion on a fully diluted basis, and a total company value of US$ 5.3 billion on a fully diluted basis.

  • Business Wire18 days ago

    Foundation Medicine to Present at Upcoming Investor Conferences

    Foundation Medicine (FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.

  • 5 Top Performing Stocks of the Best ETF of May
    Zacks23 days ago

    5 Top Performing Stocks of the Best ETF of May

    Inside the best performing stocks of the top ETF of May - ARKG.

  • Business Wire25 days ago

    Foundation Medicine and Collaborators to Present New Data at ASCO 2018 Supporting Comprehensive Genomic Profiling (CGP) to Inform Personalized Approaches in Cancer Care

    Foundation Medicine, Inc. today announced that new data generated from its comprehensive genomic profiling assays will be presented at the American Society of Clinical Oncology Annual Meeting from June 1-5, 2018 in Chicago.

  • 3 Stocks That Look Just Like eBay in 1998
    Motley Fool28 days ago

    3 Stocks That Look Just Like eBay in 1998

    These stocks are revolutionizing industries and that could make them great long-term stocks to add to your portfolio.

  • Business Wirelast month

    Foundation Medicine Establishes Immuno-Oncology Companion Diagnostics Collaboration with Merck

    Foundation Medicine, Inc. (FMI) today announced a collaboration with Merck, known as MSD outside the United States and Canada, to develop companion diagnostic tests for use with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy and the first approved immunotherapy for microsatellite instability (MSI) high or mismatch repair deficient solid tumors. The companion diagnostic tests will leverage FoundationOne CDx™, Foundation Medicine’s FDA-approved comprehensive genomic profiling (CGP) assay for all solid tumors incorporating multiple companion diagnostics. The companies will collaborate on the development of a pan-cancer companion diagnostic to measure MSI.

  • Business Wirelast month

    Foundation Medicine Receives New ADLT Status for FoundationOne CDx™ from the Centers for Medicare and Medicaid Services (CMS)

    Foundation Medicine, Inc. (FMI) today announced that under the Protecting Access to Medicare Act of 2014 (PAMA) the Centers for Medicare & Medicaid Services (CMS) approved new Advanced Diagnostic Laboratory Test (ADLT) status for FoundationOne CDx™. FoundationOne CDx is the first FDA-approved comprehensive genomic profiling assay for all solid tumors that incorporates multiple companion diagnostics. The CMS determination confirms that FoundationOne CDx meets the criteria for classification as a new ADLT.

  • 3 Healthcare Stocks Growing Over 100%
    Motley Foollast month

    3 Healthcare Stocks Growing Over 100%

    Massive sales growth at these companies could make them the perfect stocks to add to your portfolio.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes